Press Releases IN8bio, Inc.

Equities

INAB

US45674E1091

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
1.01 ^USD	0.00%		+1.00%	-26.81%

09/05	IN8bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
30/04	In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights	10/05	AQ
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma	30/04	AQ
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene and Cell Therapy 2024 Annual Meeting	25/04	AQ
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting	24/04	AQ
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference	17/04	AQ
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024	10/04	AQ
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights	15/03	AQ
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024	06/03	AQ
IN8bio to Present at Upcoming Investor Conferences	26/02	BU
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology	14/02	AQ
IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals	04/01	AQ
IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia	12/12	AQ
IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement	11/12	AQ
IN8bio Appoints Dr. Corinne Epperly to Board of Directors	07/12	AQ
IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia	05/12	AQ
IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma	20/11	AQ
IN8bio : SNO 2023 INB-200 - Clinical Update	15/11	PU
IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting	10/11	AQ
IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update	10/11	AQ
IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting	06/11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases IN8bio, Inc.

Equities

INAB

US45674E1091

Press Releases

Filters